https://doi.org/10.4081/monaldi.2010.266

Anabolic/Catabolic Imbalance in Chronic Heart Failure

Vol. 74 No. 2 (2010): Cardiac series
Submitted: December 23, 2015
Accepted: December 23, 2015
Published: December 23, 2015
Chronic Heart Failure, hormonal deficiency, Growth Hormone
Abstract Views: 845
PDF: 533
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Antonio Cittadini
antonio.cittadini@unina.it
Dipartimento di Medicina Clinica, Scienze Cardiovascolari ed Immunologiche, Università Federico II, Napoli, Italy.
Eduardo Bossone
Cava de' Tirreni - Costa d'Amalfi, Salerno, Italy.
Alberto Maria Marra
Dipartimento di Medicina Clinica, Scienze Cardiovascolari ed Immunologiche,Università Federico II, Napoli, Italy.
Michele Arcopinto
Dipartimento di Medicina Clinica, Scienze Cardiovascolari ed Immunologiche,Università Federico II, Napoli, Italy.
Emanuele Bobbio
Dipartimento di Medicina Clinica, Scienze Cardiovascolari ed Immunologiche,Università Federico II, Napoli, Italy.
Salvatore Longobardi
Merck Serono Group, Roma, Italy.
Carmine Cevara
ASL NA 1 DS 29 UO Assistenza Anziani, Divisione di Cardiologia, Italy.
Sara Di Michele
Dipartimento del Cuore e Grossi Vasi A. Reale, Università La Sapienza, Roma, Italy.
Luigi Saccà
Dipartimento di Medicina Clinica, Scienze Cardiovascolari ed Immunologiche,Università Federico II, Napoli, Italy.
A metabolic imbalance between anabolic drive and catabolic forces is commonly observed in chronic heart failure (CHF) patients, with the latter prevailing over anabolic hormones. Moreover, anabolic deficiencies are independent markers of poor prognosis. This finding represents a solid background for the implementation of therapeutic trials based on replacement therapy. The somatotropic axis (GH/IGF-1) is the most powerful anabolic axis of the body and its decline is related with a poor outcome and a worse clinical status. Growth hormone (GH) administration may enter the therapeutic arena as adjunctive treatment in patients affected by CHF and GH/IGF-1 deficiency. The T.O.S.CA. project aims at investigating the relationship between CHF and hormonal deficiency.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC

How to Cite

Cittadini, Antonio, Eduardo Bossone, Alberto Maria Marra, Michele Arcopinto, Emanuele Bobbio, Salvatore Longobardi, Carmine Cevara, Sara Di Michele, and Luigi Saccà. 2015. “Anabolic/Catabolic/Imbalance/in/Chronic/Heart/Failure”. Monaldi Archives for Chest Disease 74 (2). https://doi.org/10.4081/monaldi.2010.266.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.